0001209191-24-005486.txt : 20240502 0001209191-24-005486.hdr.sgml : 20240502 20240502212745 ACCESSION NUMBER: 0001209191-24-005486 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240501 FILED AS OF DATE: 20240502 DATE AS OF CHANGE: 20240502 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mancini Marianna CENTRAL INDEX KEY: 0001838112 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37355 FILM NUMBER: 24910538 MAIL ADDRESS: STREET 1: C/O VIKING THERAPEUTICS, INC. STREET 2: 12340 EL CAMINO REAL, STE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viking Therapeutics, Inc. CENTRAL INDEX KEY: 0001607678 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461073877 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-704-4660 MAIL ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-05-01 0 0001607678 Viking Therapeutics, Inc. VKTX 0001838112 Mancini Marianna C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 0 1 0 0 Chief Operating Officer 1 Common Stock, par value $0.00001 per share 2024-05-01 4 M 0 17999 4.68 A 366507 D Common Stock, par value $0.00001 per share 2024-05-01 4 M 0 87000 4.88 A 453507 D Common Stock, par value $0.00001 per share 2024-05-01 4 M 0 90000 5.80 A 543507 D Common Stock, par value $0.00001 per share 2024-05-01 4 M 0 35426 7.77 A 578933 D Common Stock, par value $0.00001 per share 2024-05-01 4 M 0 51000 8.52 A 629933 D Common Stock, par value $0.00001 per share 2024-05-01 4 S 0 23746 76.4045 D 606187 D Common Stock, par value $0.00001 per share 2024-05-01 4 S 0 26142 77.4933 D 580045 D Common Stock, par value $0.00001 per share 2024-05-01 4 S 0 105343 78.6476 D 474702 D Common Stock, par value $0.00001 per share 2024-05-01 4 S 0 119946 79.2945 D 354756 D Common Stock, par value $0.00001 per share 2024-05-01 4 S 0 6248 80.0753 D 348508 D Stock Option (Right to Buy) 4.68 2024-05-01 4 M 0 17999 0.00 D 2021-03-31 2030-03-31 Common Stock 17999 1 D Stock Option (Right to Buy) 4.88 2024-05-01 4 M 0 87000 0.00 D 2023-01-03 2032-01-03 Common Stock 87000 87000 D Stock Option (Right to Buy) 5.80 2024-05-01 4 M 0 90000 0.00 D 2022-01-04 2031-01-04 Common Stock 90000 0 D Stock Option (Right to Buy) 7.77 2024-05-01 4 M 0 35426 0.00 D 2021-01-03 2030-01-03 Common Stock 35426 18574 D Stock Option (Right to Buy) 8.52 2024-05-01 4 M 0 51000 0.00 D 2024-01-03 2033-01-03 Common Stock 51000 153000 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 1, 2024. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $76.09 to $76.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $77.00 to $77.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $78.00 to $78.9983, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $79.00 to $79.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $80.02 to $80.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date. One-third of the shares subject to the option vested on each one year anniversary of the grant date. /s/ Michael Morneau as Attorney-in-Fact 2024-05-02